Cooper Companies (The) vs Cardinal Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (75 vs 79)
Cooper Companies (The) logo

Cooper Companies (The)

LeaderHealthcare Tech

Enterprise

San Ramon CA contact lenses and fertility devices (NASDAQ: COO) $3.87B FY2024 revenue (+9%); CooperVision MiSight myopia management, CooperSurgical IVF consumables, competing with J&J Vision and Alcon.

AI VisibilityBeta
Overall Score
B75
Category Rank
#77 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
78
Gemini
74

About

The Cooper Companies, Inc. is a San Ramon, California-based medical device company — publicly traded on the NASDAQ (NASDAQ: COO) as an S&P 500 Health Care component — operating two segments: CooperVision (soft contact lenses for vision correction globally — the second-largest contact lens manufacturer worldwide) and CooperSurgical (fertility and women's health medical devices including IVF laboratory consumables, assisted reproductive technology products, and gynecological surgical instruments) through approximately 15,000 employees in 130 countries. In fiscal year 2024 (ending October 2024), Cooper Companies reported revenues of $3.87 billion (+9% organic growth), with CooperVision generating $2.56 billion from daily, biweekly, and monthly contact lens sales across sphere, toric (astigmatism-correcting), and multifocal (presbyopia-correcting) lens categories, and CooperSurgical generating $1.31 billion from fertility clinic consumables and women's health surgical products. CEO Albert White has executed CooperVision's strategy of capturing the premium daily silicone hydrogel lens market: silicone hydrogel material (higher oxygen permeability improving eye health versus conventional hydrogel) commands a 20-30% price premium over conventional daily lenses, and Cooper's MyDay (premium daily silicone hydrogel) and clariti (value silicone hydrogel) brands compete across price tiers against Johnson & Johnson Vision's Acuvue Oasys and CIBA Vision's AIR OPTIX brands for the global market shift toward dailies — the fastest-growing contact lens modality as patients prefer the convenience and hygiene of discarding lenses after each day's wear.

Full profile
Cardinal Health logo

Cardinal Health

LeaderHealthcare Tech

Enterprise

Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.

AI VisibilityBeta
Overall Score
B79
Category Rank
#19 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
75
Gemini
77

About

Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.

Full profile

AI Visibility Head-to-Head

75
Overall Score
79
#77
Category Rank
#19
80
AI Consensus
90
stable
Trend
stable
79
ChatGPT
79
78
Perplexity
75
74
Gemini
77
77
Claude
77
71
Grok
79

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Integrations

Both integrate with
Only Cooper Companies (The)
Only Cardinal Health
Cooper Companies (The) is classified as company. Cardinal Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.